Krystal Biotech, Inc. (KRYS) News
Filter KRYS News Items
KRYS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KRYS News Highlights
- For KRYS, its 30 day story count is now at 5.
- Over the past 15 days, the trend for KRYS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about KRYS are DEC, DRUG and ODD.
Latest KRYS News From Around the Web
Below are the latest news stories about KRYSTAL BIOTECH INC that investors may wish to consider to help them evaluate KRYS as an investment opportunity.
Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the UpgradeKrystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB). |
12 Best Genomics Stocks To Buy NowIn this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […] |
Here’s Why TimesSquare Capital Management U.S. Small Cap Growth Strategy Added Krystal Biotech (KRYS)TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned -3.67% (net), compared to -7.32% return for the Russell 2000 Growth Index. Year-to-date the fund returned 11.56% (net) compared to 9.59% return for […] |
Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis BullosaIf approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first timeVYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today anno |
Goldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside PotentialFor investors seeking a solid return, few stock segments offer a better mix of risk, reward, and opportunity than healthcare stocks. While these stocks are known for their notoriously long product lead times and high overhead costs, they are also known for their ability to turn sharply on a new catalyst and generate strong returns. That dynamic is part and parcel of the biopharmaceutical research field. The biotech companies spend their capital and efforts – huge amounts of each – on the discove |
This Stock Has Quadrupled in 5 Years. Can It Do It Again?It's been a solid year for Krystal Biotech (NASDAQ: KRYS), a midcap company focusing on developing gene therapies, as it has easily outperformed the market this year. In May, the U.S. Food and Drug Administration (FDA) gave the green light to the company's Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa (DEB), sometimes called butterfly skin. Krystal Biotech focuses on rare skin diseases, of which DEB is a prime example. |
Krystal Biotech to Present at the Stifel 2023 Healthcare ConferencePITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Stifel 2023 Healthcare Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host inve |
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2023 Earnings Call TranscriptKrystal Biotech, Inc. (NASDAQ:KRYS) Q3 2023 Earnings Call Transcript November 6, 2023 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $-0.69, expectations were $-1.1. Operator: Thank you for standing by and welcome to the Krystal Biotech Third Quarter 2023 Earnings Conference Call. As a reminder today’s conference call is being recorded. I would now […] |